Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Investigator and Patient Blind Placebo-controlled Parallel Group First in Human and Proof of Concept Study to Evaluate the Safety Tolerability and Efficacy of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ

Next Previous
Trial Profile

A Randomized Investigator and Patient Blind Placebo-controlled Parallel Group First in Human and Proof of Concept Study to Evaluate the Safety Tolerability and Efficacy of CLL442 in Patients With Cutaneous Squamous Cell Carcinoma in Situ

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 06 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CLL 442 (Primary)
  • Indications Carcinoma; Squamous cell cancer
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

Most Recent Events

  • 29 Sep 2020 Status changed from completed to discontinued.
  • 10 Dec 2018 Status changed from recruiting to completed.
  • 21 Nov 2018 Planned End Date changed from 2 Nov 2018 to 16 Aug 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top